Prolacta honors and values breastfeeding mothers and their committment to the health of babies
Clinically proven to improve health outcomes of critically ill preemies
Committed to scientific and clinical research in breast milk
Prolact Product Safety

Board of Directors

John Bacich Jr.

Chairman of the Board

Mr. Bacich has been involved in the biopharmaceutical industry for 40 years. Most of that experience was with Baxter Healthcare beginning in 1968 and retiring in 1998. He held a variety of positions including quality management, research and development, global manufacturing operations, and general management leading to the presidency of what is now called the Bioscience Division of Baxter Healthcare.

In his capacity as president he was responsible for the plasma products worldwide and the development of the recombinant proteins business. He was also a charter board member of the Plasma Protein Therapeutics Association which is the only industry association for plasma products producers and their recombinant equivalents.

Mr. Bacich remains active in the industry as a consultant and is a member of the EMT for Inspiration Biopharmaceuticals. He is also a past director of the Southern California Hemophilia Society. Mr. Bacich holds a BS in Microbiology from California State University at Long Beach.

David Brailer, Prolacta Board Member
David Brailer
Board Member

David Brailer

Board Member

David founded the health information technology program at The Wharton School of Business, with in the University of Pennsylvania. He also taught health management and economics in their MBA program and lectured in The Wharton Executive Education Program. David was also an active patient-care physician in general medicine and in immune deficiency at the University of Pennsylvania.

David also founded CareScience as a spin out from The Wharton School and led it through several financings, strategic partnerships, an IPO and a strategic sale. Under David’s leadership, CareScience established itself as an early leader in the use of the internet to share health information and to improve the quality of care across the United States.

David was appointed the nation’s first National Coordinator for Health-Information Technology in May of 2004. In this role David was the architect of the nation’s effort to bring our health care system into the information age. David is now a managing partner and CEO at Health Evolution Partners, where he came aboard in 2007. David joined Prolacta Bioscience Board of Directors in 2014, and also sits on three other boards for CenseoHealth, Optimal Radiology and Walgreen Company.

Ned Brown

Board Member

Ned Brown is a Partner at Health Evolution Partners, focusing on investments in the life sciences area, including medical devices/products, specialty pharmaceuticals and outsourcing services for the life sciences industry. Ned has been involved in the healthcare industry for over 25 years, as an investor, board member and advisor to a broad range of companies in all sectors of the industry.

Prior to joining HEP as an advisor in June 2010 and full time in January 2011, Ned was a Managing Director at TPG Biotech, from June 2007 to June 2010, where he focused on medical device investments. Prior to TPG, Ned co-founded in June 2004, and was a Managing Director of, Healthcare Investment Partners, a healthcare focused growth equity investment firm, founded with Henry Wendt, the former CEO of SmithKline Beecham and Chairman of Donaldson Lufkin and Jenrette's healthcare investment arm, Global Healthcare Partners. Prior to HIP, Ned spent 17 years as an advisor, investor, and investment banker in all sectors of the healthcare industry, most recently as a Managing Director and Head of the West Coast Healthcare Group for Credit Suisse.

Ned has served on both private and public company boards, including his current role at Cardiovascular Systems (NASDAQ:CSII), and past roles at Angiotech Pharmaceuticals, Tandem Diabetes and Novasom (formerly Sleep Solutions). Past investments include control buyouts of Charles River Labs and Wilson Greatbatch, growth equity investments in Cardiovascular Systems, NxStage Medical and Prometheus Laboratories, and venture investments in Access Closure, Animas, Cardiovascular Systems (formerly Relpidyne), Embolic Protection, Novasom, Spinal Concepts and Tandem Diabetes.

Sally Crawford

Board Member

Sally Crawford has been a healthcare consultant in New Hampshire since 1997 working with health care providers, regulators, investors, employers and managed care payers on strategic marketing and reimbursement projects. From 1985 – 1997, Sally served as Chief Operating Officer of Healthsource, Inc., a publicly traded NYSE HMO and managed care company before it was acquired by CIGNA. As COO, Sally organized the development of the Company’s management, operating systems, marketing strategies and supported strategic alliances with physicians, employers, hospitals, insurers and other health care companies.

Sally currently serves on the Board of Directors of five health care companies, including Hologic, Inc. (NASDAQ: HOLX), Insulet Corporation (NASDAQ: PODD), Universal American (NYSE: UAM), Exact Sciences (NASDAQ: EXAS) and Zalicus, Inc (NASDAQ:ZLCS). Prior Board positions include Cytyc Corporation (NASDAQ: CYTC), Chittenden Corporation (NYSE: CHZ) and Harborside Healthcare (NYSE: HBR).

Sally earned a Bachelor’s degree from Smith College and a Master’s degree in Communications from Boston University.

Scott A. Elster

Chief Executive Officer

Mr. Elster has over 20 years of experience in the biosciences and financial sectors. His experience encompasses planning, finance and strategy development, supply chain, and operations. Most recently, Mr. Elster was director of operations and supply chain at Clinical Micro Sensors (CMS), a Motorola Company. There, Mr. Elster successfully prepared operations for the company's first commercial launch, including FDA approval of the GMP manufacturing facility. He led the quality control function, the manufacturing team, and operational strategy development. His team was also responsible for materials and inventory management, as well as distribution and warehousing.

For over 13 years at Baxter, Mr. Elster's management work was focused directly on plasma products worldwide. His roles included manager of strategic planning, business development, finance and strategy for the hyperimmune business unit, and director of global supply chain. Mr. Elster began his career at Deloitte and Touche as a financial statement auditor, and is a current board member and past chairman of the board for Monrovia Growers.

Mr. Elster received a Bachelor of Science degree from California State University, Northridge, and a Master of Business degree from the Anderson Graduate School of Management at University of California, Los Angeles.

Frank H. Foster

Chairman Emeritus

Mr. Foster is the Managing Director of the Gideon Hixon Fund, the venture capital investment vehicle for the Hixon Family and a venture partner of Draper Fisher Jurvetson Frontier. The Gideon Hixon Fund and its predecessor entities (HixVen and Southwest Venture Partnerships) have a long history in venture capital beginning in the 1970s. The group's venture capital investments include Apple Computer (NASDAQ & NYSE: AAPL) and Dell (NASDAQ: DELL) as well as more recent successes including CORSolutions (acquired by Matria), Medior (acquired by AOL), Security Dynamics (acquired by RSA), WebCal (acquired by Yahoo) and Xiotech (acquired by Seagate). Prior to that, he was a General Partner of Allen & Buckeridge PTY LTD, a leading Australian venture capital firm with approximately $250 million under management. At Allen & Buckeridge he led investment efforts into Hitwise, eKit, Wishlist and Next Generation Entertainment.

Mr. Foster also has extensive operational experience through his roles at Virtual Music Entertainment (sold to NAMCO), Contexture Systems and Prophecy Development Corporation. Recently, he acted as an independent director and consultant to where he helped guide the company through its successful sale to SBC Communications (NYSE: SBC) and Bell South (NYSE: BLS) in November 2004. He was also a director of Cogent Data technologies through its successful sale to Adaptec Inc (NASDAQ: ADPT) in June 1996. Mr. Foster is currently a member of the board of directors for Prolacta Bioscience,, Hixon Properties Incorporated, and Our Happy Child Productions. He received his MBA from The Harvard Business School and a BA cum laude from Harvard University.

Dan Janney

Board Member

Dan Janney joined Alta Partners immediately following the firm’s founding in 1996, and was a co-founder of the Alta BioPharma effort.

Mr. Janney focuses on investments in biopharmaceutical products and therapeutics. He has been directly involved in the funding and development of over 25 life sciences companies. He is currently on the board of directors of a number of companies, including Alba Therapeutics, DiscoveRx, Lithera and ViroBay. In addition, he led Alta’s investments in ChemGenex Pharmaceuticals, CoTherix, Definity Health, Dynavax, Endonetics, Ilex Oncology, InterMune, LJL Biosystems and Mako Surgical.

Prior to joining Alta, Mr. Janney was a senior investment banker at Montgomery Securities, focusing on life sciences companies. He is also a member of the advisory board for the Rebecca and John Moores Cancer Center at University of California, San Diego.

Mr. Janney holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.

Ernie Strapazon

Board Member

Mr. Strapazon has been involved with nutrition, health and wellness products for over thirty years. Most of this experience was with Nestlé where he held a variety of positions including brand management, global strategic planning, innovation/renovation and general management. He led a pioneering effort to establish the Nestlé Infant Nutrition business in the US.

As President, Nutritional Products Division and Nestlé Nutrition – USA, his responsibilities included Clinical Nutrition (Peptamen, Carnation Instant Breakfast) , Performance Nutrition (PowerBar) and Infant Nutrition (Good Start Infant Formulas).

Mr. Strapazon is also a board member of Nellson Nutraceutical, LLC. He holds an undergraduate degree in Chemistry from Northwestern University and a PhD in Biochemistry and MBA from the University of Chicago.

Follow Us!